Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In non-pathological conditions the clearance of cerebral Aβ exceeds its production [9].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [9]
In the citing paper
“we adapted an in vivo stable isotopic labeling kinetics technique previously described in humans (43).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [43]
In the citing paper
“which is approximately 4-times slower than the turnover rate for the total CNS Aβ peptide (Fig. 6) [31]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [31]
In the citing paper
“The interstitial concentration of Aβ is higher in awake than in sleeping rodents and humans”
From Sleep Drives Metabolite Clearance from the Adult Brain (2013) · cites this paper as [15]
In the citing paper
“In prior SILK studies (19), plasma 13C6-leucine enrichment was found to adequately represent 13C6 labeling in the precursor pool for Aβ synthesis.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several earlier studies have shown that some plasma Aβ can enter the CN”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“In Down syndrome, three copies of APP result in increased production of Aβ, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref”
Garlick, P. J., McNurlan, M. A., & Preedy, V. R. (1980) · Biochemical Journal · doi:10.1042/bj1920719 · Cited by 973
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Cerebrospinal Fluid in Diseases of the Nervous System.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 657
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Cited by
Items 501–600 of 627
Purification and Quantification of Neural α-synuclein
Mollenhauer, B., & Schlossmacher, M. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00041-5 · Cited by 5
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 3
Zhdanov, V. P. (2016) · Mathematical Biosciences · doi:10.1016/j.mbs.2016.04.009 · Cited by 2
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 4
Power tools for Alzheimer’s disease – an electrochemical preamp for Aβ
Zetterberg, H., & Hammarström, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07730.x · Cited by 2
Targeting nascent soluble Aβ42 for potential Alzheimer drug development
Zhang, M., Hausmann, L., & Song, W. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12156 · Cited by 2
Raybon, J. J., & Albright, C. F. (2010) · Annals of Neurology · doi:10.1002/ana.21929 · Cited by 2
Usefulness of Cerebrospinal Fluid Biomarkers in Diagnosis of Early Alzheimer's Disease
Herukka, S. (2007) · Cited by 2
Preface: Mass spectrometry in Alzheimer disease
Hanrieder, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15512 · Cited by 2
Neuroimaging and molecular biomarkers of dementia
Polyakova, T., & Араблинский, А. В. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171176216-22 · Cited by 1
Gene Therapy for Neurological Disorders: Molecular Approaches for Targeted Treatment
Malviya, R., Singh, A. K., Goyal, P., & Sundram, S. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003494102 · Cited by 1
Glymphatic system, sleep, neurodegeneration
Gorbachevskii, A. V., Kicherova, O. A., & Рейхерт, Л. И. (2024) · Журнал высшей нервной деятельности им И П Павлова · doi:10.31857/s0044467724030024 · Cited by 9
Neuropathological Diagnoses of Dementia
Liščić, R. M. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_6 · Cited by 1
Leckey, C. A., Giovannucci, T. A., Murphy, E. C., Moncur, E. M., Tariq, K., Aslanyan, A., Schöll, M., Srikrishna, M., Coath, W., Barker, S., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag029 · Cited by 1
Self-citationSpatiotemporal characterization of Alzheimer disease pathology in living human brain tissue
Aslanyan, A., Mukherjee, S., Moncur, E. M., Szadziewska, A., He, Y., Kac, P. R., Coyle, R. A., Camporesi, E., Sato, C., Ghoshal, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76494-4 · Cited by 1
Self-citationBiomarkers of Neurological Disorders
Jain, K. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-272-8_4 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Ashraf, A., Mehta, P. D., & Edison, P. (2012) · Reviews in Clinical Gerontology · doi:10.1017/s0959259812000160 · Cited by 1
Rule-based modelling and simulation of drug-administration policies
Bortolussi, L., Krüger, T. B., Lehr, T., & Wolf, V. (2015) · ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) · doi:10.5555/2873003.2873012 · Cited by 1
Protein seeding in Alzheimer’s disease and Parkinson’s disease: Similarities and differences
Ibrahim, T. (2014) · World Journal of Neurology · doi:10.5316/wjn.v4.i4.23 · Cited by 1
Biomarkers in vascular dementia
Wallin, A., & Pirttilä, T. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511575976.008 · Cited by 1
Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00001-x · Cited by 1
Masters, C. L., Gu, B. J., Laws, S. M., Lim, Y. Y., Roberts, B. R., Villemagne, V. L., & Beyreuther, K. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00003-1 · Cited by 1
Fantini, J., & Yahi, N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800111-0.00011-4 · Cited by 1
Abeta Predictor of Alzheimer Disease Symptoms
Sephton, C. F., & Yu, G. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.875 · Cited by 1
Dorsemans, A.-C. (2018) · theses.fr (ABES) · doi:10.70675/5837f59fz9b16z4f74z8152z29531da792b6 · Cited by 2
Ibrahim, T. (2015) · TSpace (University of Toronto) · Cited by 1
Brain geometry matters in Alzheimer’s disease progression: a simulation studyPreprint
Hoore, M., Kelling, J., Sayadmanesh, M., Mitra, T., Schips, M., & Meyer‐Hermann, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.24.220228 · Cited by 1
Biomarkers of Disorders of the Nervous System
Jain, K. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-685-6_7 · Cited by 1
Sabbagh, J. J. (2013) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/4478299
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Stephen, F., Zhou, H., Wang, S., Herath, K. B., Douglas, G., Thomas, P., Kasumov, T., & Brian, K. (2012) · InTech eBooks · doi:10.5772/29573 · Cited by 1
Biomarkers and Surrogate Markers in Drug Development
Cutler, N. R., Sramek, J. J., Murphy, M. F., Riordan, H., Bieck, P. R., & Carta, A. (2010) · Wiley eBooks · doi:10.1002/9781444318579.ch4
Microglial properties in health and disease
Krabbe, G. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15999
Role of Oxidatively Stressed Lipids in Amyloid Formation and Toxicity
Axelsen, P. H., & Komatsu, H. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch27
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Alzheimer's disease : a neurodegenerative disease : an honors thesis (HONRS 499)
McCormick, K. I. (2008) · Cardinal Scholar (Ball State University)
Tall, M. L., Diouf, E., Filali, S., Sauvinet, V., Laleye, D., Dhelens, C., Salmon, D., Gabert, L., Nugue, G., Sandre-Ballester, C., et al. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.02.002
INVESTIGATORS ARE FINDING NEW BIOCHEMICAL AND RADIOLOGIC MARKERS OF PRECLINICAL ALZHEIMER DISEASE
Moyer, P. (2006) · Neurology Today · doi:10.1097/00132985-200611070-00011
FIRST MEASUREMENTS SHOW RAPID TURNOVER OF AMYLOID BETA IN HUMAN BRAIN
Robinson, R. (2006) · Neurology Today · doi:10.1097/00132985-200608150-00002
Martone, R. L., Snyder, R. H., Xu, A. S. L., & Reams, R. Y. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-012-0015-4
Commentary on “Biomarkers in Alzheimer's disease drug development.” Can't live without 'em
Aisen, P. S. S. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.006
Assessment of old and new proteins: A novel methodology
Johnson, M. L., & Nair, K. S. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.05.006
Linking Molecular Neurobiology to Therapeutic Approaches for Alzheimer’s Disease with PET
Luiten, P. G. M., Masman, M. F., Dobos, N., Nyakas, C. J., de Vries, E. F. J., Dierckx, R., & Eisel, U. L. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_20
Translational Approaches in Alzheimer’s Disease
Wood, S. J., & Vargas, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803460-6.00007-6 · Cited by 1
Aronsen, E. (2009) · Duo Research Archive (University of Oslo)
Dey, A., Wu, J., & Kirkpatrick, D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0992-6_15
The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease
Selkoe, D. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00001-0
Giunta, B. N., Minagar, A., & Fernandez, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2410-3_22
Crisp, M. J. (2016) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7c24tq6
Price, D. L., Savonenko, A. V., Li, T., & Wong, P. C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.009
Antisense Oligonucleotides for Amyotrophic Lateral Sclerosis
Self, W. K., & Miller, T. M. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_6 · Cited by 1
Some Biochemical Markers in Patients with Alzheimer's Disease.
Khanahmadi, M., Farhud, D. D., Malmir, M., & Orang, S. (2016) · PubMed Central
The Search for Biomarkers in Alzheimer's Disease
Meiliana, A., & Wijaya, A. (2010) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v2i1.107 · Cited by 3
Guest, P. N. (2016) · St Andrews Research Repository (St Andrews Research Repository) · Cited by 1
Cantone, J. L., Polson, C., Cong, W., Guss, V., Ahlijanian, M., Meredith, J., & Drexler, D. (2017) · Analytical Methods · doi:10.1039/c7ay00869d
Lorette, A. (2012)
Self-Uptake by Microglia Contributes to Amyloid Beta-Induced Receptor-Mediated Pinocytosis 4 P2Y
Duan, S., Lou, H., Zhang, J., Li, X., Wang, H., Li, H.-Q., Chen, C., Dou, Y., Wu, H., & Liu, Y. (2014)
Étude du rôle de l’angiotensine II sur les fonctions cérébrales
Duchemin, S. (2016) · doi:10.71781/30218
The Role of Chromatography in Alzheimer’s Disease Drug Discovery
Grushka, E., & Grinberg, N. (2016) · CRC Press eBooks · doi:10.1201/9781315370385-7
Exploring the Role of the DEK Oncogene as a Novel Player in Learning and Memory
Ghisays, V. (2017) · OhioLink ETD Center (Ohio Library and Information Network)
Targeting Astrocytes With Viral Gene Therapy for Alzheimer’s Disease
Rosenthal, Z. P., Kraft, A. W., Czerniewski, L. R., & Lee, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00005-3 · Cited by 1
Smotherman, J. M. (2017) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc984161
Klein, E. (2017) · Open Archive Toulouse Archive Ouverte (University of Toulouse) · Cited by 1
Neuroimaging and Molecular Biomarkers for Dementia
Polyakova, T., & Араблинский, А. В. (2019) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-019-00747-7
Paik, S. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0371596
Multimodal Chemical Imaging of Amyloid Plaque Pathology in Alzheimer’s Disease
Michno, W. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Hurley, D. (2019) · Neurology Today · doi:10.1097/01.nt.0000579948.44540.5d
McKeever, P. M. (2018) · TSpace (University of Toronto)
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., & Zetterberg, H. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_9
Role of IL-33/ST2 Axis in Chronic Inflammatory Neurological Disorderss
Dimitrijević, J., Arsenijević, A., Milovanović, M., Stojanović, B., Arsenijević, D., Milovanović, J., & Arsenijević, N. (2021) · Serbian Journal of Experimental and Clinical Research · doi:10.2478/sjecr-2020-0038
Härd, T., & Sandberg, A. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13271974.14628100
Cellular Mechanisms of Dementia: Animal and Human Studies
Gan, L. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0054
Duffin, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736901473.793567387
Bateman, R. J., Siemers, E., Mawuenyega, K. G., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., Paul, S. M., & Holtzman, D. M. (2010) · Annals of Neurology · doi:10.1002/ana.21930
Self-citationThe Role of Chromatography in Alzheimer’s Disease Drug Discovery
(2016) · Advances in chromatography · doi:10.1201/9781315370385-3
Biomarcadores amiloidogênicos na síndrome de Down
Bram, J. M. D. F. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-20092023-163847 · Cited by 1
Time Factor Hypothesis: Towards Identifying Onset of Alzheimer’s Disease in Younger Adults
Anyaiwe, O. E. D., Konwe, C. S., & Gwarzo, Z. (2023) · Series of Clinical and Medical Case Reports and Reviews · doi:10.54178/2993-3579.v1i6a2019
Fathallah, S. S. (2023) · theses.fr (ABES) · doi:10.70675/cd31edacz7e53z4d37zaf55z5dfcf1f9ba3f
Enabling Population Protein Dynamics Through Bayesian Modeling
Lehmann, S., Vialaret, J., Gabelle, A., Bauchet, L., Villemin, J.-P., Hirtz, C., & Colinge, J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae484
Metabolism of Aβ: Catabolic and glymphatic systems
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00008-5
Quantifying protein kinetics in vivo: influence of precursor dynamics on product labeling
Yao, H., Kelley, S., Zhou, D., VanSickle, S., Wang, S., Piesvaux, J., Zhou, H., Chen, H., McKenney, D., McLaren, D. G., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2024
Хронопатологические и инструментальные предикторы нейродегенеративных заболеваний
Эдуардовна, В. Т., Крымская, О. С., Gorbachevskii, A. V., & Бимусинова, М. Т. (2024) · doi:10.32878/devi.24-8-02(15)-42-48
Autophagy: Its Role In Cellular Homeostasis And Various Diseases
Hritani, N. (2024) · International journal of high school research · doi:10.36838/v6i9.16
Analyzing Different Hypotheses for Alzheimer’s Disease
Kou, D. (2025) · Frontiers in Medical Science Research · doi:10.25236/fmsr.2025.070103
Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_15
Bermúdez, I., Gómez-Vargas, B., Mardal, K., Rubiano, A. E., & Ruíz-Baier, R. (2026) · Computer Methods in Applied Mechanics and Engineering · doi:10.1016/j.cma.2026.119475
Shiiki, T., & Ohtsuki, S. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00424
Zakaria, J. A. D. (2013) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7125qnb
Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603541
Self-citationDeveloping translational kinetic biomarkers for neurodegenerative disease
Leckey, C. A. (2023) · UCL Discovery (University College London)
Colony Stimulating Factor 1 Receptor and Blood-Brain Barrier Maintenance
Delaney, C. (2021) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Longmuir, M. (2024) · Scholarship@Western (Western University)
La Proteina Tau: ruolo nucleare, trasporto e implicazioni patologiche nelle Tauopatie
Bernini, F. (2024) · Electronic Theses and Dissertations Repository (University of Pisa)
Shibah, S. R. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5969296
Liu, Y.-C., Hsu, W.-L., Ma, Y.-L., Yin, C.-Y., & Lee, E. H.-Y. (2026) · Journal of physiological investigation. · doi:10.4103/ejpi.ejpi-d-25-00064
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629
Metadata
- Authors
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Venue
- Nature Medicine
- Published
- 2006-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 856-861
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2983090
- OpenAlex
- W2171259749
- Cited by
- 599
- References
- 41
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 33 · 2023: 27 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 34 · 2018: 23 · 2017: 35 · 2016: 36 · 2015: 40 · 2014: 31 · 2013: 30 · 2012: 40
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- American Academy of Neurology
- National Institutes of Health (5p41rr000954-34)
- National Institute on Aging (L30 AG024455, K08AG027091, P 50 AG05681, P50AG005681)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 056341, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-000954, M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, cerebrospinal fluid, amyloid precursor protein, biomarkers
- MeSH terms
- Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Protein Conformation, Biomarkers, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.